Request Demo
Last update 24 May 2025
Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
Last update 24 May 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms HS629 |
Target |
Action inhibitors |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)CTR20180258
一项在晚期实体瘤骨转移受试者皮下注射重组抗 RANKL 全人源单克隆抗体注射液的多中心、 开放、 I 期临床研究
[Translation] A multicenter, open-label, phase I clinical study of subcutaneous injection of a recombinant anti-RANKL fully human monoclonal antibody in subjects with advanced solid tumor bone metastases
100 Clinical Results associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
Login to view more data
100 Deals associated with Recombinant human anti-RANKL antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 12 Apr 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free